JPH0586931B2 - - Google Patents
Info
- Publication number
- JPH0586931B2 JPH0586931B2 JP61153673A JP15367386A JPH0586931B2 JP H0586931 B2 JPH0586931 B2 JP H0586931B2 JP 61153673 A JP61153673 A JP 61153673A JP 15367386 A JP15367386 A JP 15367386A JP H0586931 B2 JPH0586931 B2 JP H0586931B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- glutathione
- dicarboxyethyl
- anticoagulant
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PWCIUOASSAHGHI-WPZUCAASSA-N 2-[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSC(CC(O)=O)C(O)=O PWCIUOASSAHGHI-WPZUCAASSA-N 0.000 claims description 14
- PWCIUOASSAHGHI-UHFFFAOYSA-N S-(1,2-Dicarboxyethyl)glutathione Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSC(CC(O)=O)C(O)=O PWCIUOASSAHGHI-UHFFFAOYSA-N 0.000 claims description 14
- 108700005486 S-(1,2-dicarboxyethyl)glutathione Proteins 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000701 coagulant Substances 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 230000023555 blood coagulation Effects 0.000 description 13
- 108010024636 Glutathione Proteins 0.000 description 12
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 12
- 239000003146 anticoagulant agent Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229960003180 glutathione Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000002429 anti-coagulating effect Effects 0.000 description 10
- 229940127219 anticoagulant drug Drugs 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004019 antithrombin Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000006408 oxalic acid Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- -1 1,2-dicarboxyethyl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- JQWABENXVMJJMW-NPPUSCPJSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-(2-carboxypropylsulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C(C)CSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O JQWABENXVMJJMW-NPPUSCPJSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000545744 Hirudinea Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- XPKKFTKCRVIDAG-WUCPZUCCSA-N S-(2-succinyl)-L-cysteine Chemical compound OC(=O)[C@@H](N)CSC(C(O)=O)CC(O)=O XPKKFTKCRVIDAG-WUCPZUCCSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 2
- 229940039790 sodium oxalate Drugs 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- DJMPKBWSUHIYKQ-PPSBICQBSA-N C(=O)(O)C(CC(=O)O)N[C@H](C(=O)O)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O Chemical compound C(=O)(O)C(CC(=O)O)N[C@H](C(=O)O)CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O DJMPKBWSUHIYKQ-PPSBICQBSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000005053 encephalomalacia Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61153673A JPS638337A (ja) | 1986-06-30 | 1986-06-30 | 抗血液凝固剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61153673A JPS638337A (ja) | 1986-06-30 | 1986-06-30 | 抗血液凝固剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS638337A JPS638337A (ja) | 1988-01-14 |
| JPH0586931B2 true JPH0586931B2 (ru) | 1993-12-14 |
Family
ID=15567670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61153673A Granted JPS638337A (ja) | 1986-06-30 | 1986-06-30 | 抗血液凝固剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS638337A (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02129127A (ja) * | 1988-11-04 | 1990-05-17 | Sumitomo Seika Chem Co Ltd | 改良された赤血球保存液 |
| JPH0723733B2 (ja) * | 1989-01-23 | 1995-03-15 | 日清紡績株式会社 | ディスクブレーキ用パッドの脱落防止装置 |
| JP2815179B2 (ja) * | 1989-07-14 | 1998-10-27 | 千寿製薬株式会社 | 抗炎症および／または抗アレルギー剤 |
| JP2919870B2 (ja) * | 1989-09-29 | 1999-07-19 | 千寿製薬株式会社 | 肝障害抑制剤 |
| EP0480060B1 (en) * | 1990-04-26 | 1996-10-23 | Senju Pharmaceutical Co., Ltd. | S-(lower fatty acid)-substituted glutathione derivative |
| US5212159A (en) * | 1991-02-27 | 1993-05-18 | Senju Pharmaceutical Co., Ltd. | Anticataract composition |
| CA2123555A1 (en) * | 1993-06-07 | 1994-12-08 | Shinji Ohmori | Intraocular irrigating solution |
| JP5267096B2 (ja) * | 2008-12-12 | 2013-08-21 | 住友化学株式会社 | Ｎ，Ｓ−ジ−ｔｅｒｔ−ブトキシカルボニルグルタチオン蛍光誘導体及びそれを中間体として用いるグルタチオン蛍光誘導体の製造方法 |
-
1986
- 1986-06-30 JP JP61153673A patent/JPS638337A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS638337A (ja) | 1988-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Markwardt et al. | Pharmacological studies on the antithrombotic action of hirudin in experimental animals | |
| JP3953510B2 (ja) | 医薬組成物 | |
| EP0233279B1 (de) | Neuartige verwendung von taurolin | |
| Gulati et al. | Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglogbin on the regional circulation and systematic hemodynamics | |
| JPS6218401A (ja) | 結合組織病理において有効な医薬の製造に使用する多糖およびオリゴ糖 | |
| WO1982000095A1 (en) | Thrombosis-prophylatic and curing agent | |
| JPH0586931B2 (ru) | ||
| JPH06192291A (ja) | 新規ペプチドとそれを用いた血小板凝集抑制剤及び血液凝固抑制剤 | |
| SU1456008A3 (ru) | Способ получени кислотно-аддитивных солей амидиновых соединений | |
| JPS6357407B2 (ru) | ||
| JPS61112018A (ja) | 線溶増強剤 | |
| JPH09176040A (ja) | ヘパリンコファクターｉｉの医薬用途 | |
| DE69427363T2 (de) | Plättchenaggregationsinhibierende peptide | |
| JPS6058927A (ja) | 放射能標識血小板製剤 | |
| JPH0597674A (ja) | コラーゲナーゼ阻害剤 | |
| Hampton | Trends in the development of antithrombotic agents | |
| EP0369035A1 (en) | Agent for treating pancreatitis or the like | |
| US3715434A (en) | Iodopeptide anticoagulants | |
| Sorenson et al. | A Synthetic Anticoagulant: A Polysulfuric Acid Ester of Polyanhydromannuronic Acid (Paritol) Experience with Its Use in Man | |
| JPS61145122A (ja) | 利尿作用を有する医薬 | |
| JPH0952843A (ja) | 急性腎不全治療剤 | |
| JPS63132843A (ja) | 抗炎症剤 | |
| JP2825283B2 (ja) | 血管障害判定法 | |
| JPH07309746A (ja) | システイン誘導体を含有した注射剤 | |
| JPS62195328A (ja) | ２−ヒドロキシ−３−イソプロピル−５，６−ジメチルピラジンからなる循環・代謝改善剤 |